JKenser
Long/short equity, biotech, small-cap

Why Neuralstem Has Plenty Of Upside In The Short Term

Neuralstem almost to third base with NSI-566 for Lou Gehrig's Disease...

Neuralstem (NYSEMKT:CUR) recently finished up their Phase 2 trial for ALS using their NSI-566 Neural Stem Cells on July 30th, according to a newly released video by the Michigan ALS Association. In that video, Dr. Eva Feldman gives a presentation on her work and a tiny glimpse into what we can expect from the Phase 2 results, and a probable upcoming Phase 3 trial.

In her video, Dr. Feldman discusses the end of the Phase 2 trial occurring on July 30th and her locking the data and sending it over to the FDA on August 4th. She states that she is "jazzed" about sending the data to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details